Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 4-aminopyridine and cerebellar gait: a retrospective case series.

Literature DB >> 22760944

4-aminopyridine and cerebellar gait: a retrospective case series.

Roman Schniepp, Max Wuehr, Maximilian Neuhaeusser, Ann Kathrin Benecke, Christine Adrion, Thomas Brandt, Michael Strupp, Klaus Jahn.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2012 PMID： 22760944 DOI： 10.1007/s00415-012-6595-2

Source DB: PubMed Journal: J Neurol ISSN： 0340-5354 Impact factor: 4.849

× No keyword cloud information.

10 in total

1. Long-term effects of coordinative training in degenerative cerebellar disease.

Authors: Winfried Ilg; Doris Brötz; Susanne Burkard; Martin A Giese; Ludger Schöls; Matthis Synofzik
Journal: Mov Disord Date: 2010-10-15 Impact factor: 10.338

2. The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.

Authors: Karina Alviña; Kamran Khodakhah
Journal: J Neurosci Date: 2010-05-26 Impact factor: 6.167

3. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.

Authors: Andrew D Goodman; Theodore R Brown; Keith R Edwards; Lauren B Krupp; Randall T Schapiro; Ron Cohen; Lawrence N Marinucci; Andrew R Blight
Journal: Ann Neurol Date: 2010-10 Impact factor: 10.422

4. 4-Aminopyridine improves gait variability in cerebellar ataxia due to CACNA 1A mutation.

Authors: Roman Schniepp; Max Wuehr; Nibal Ackl; Adrian Danek; Thomas Brandt; Michael Strupp; Klaus Jahn
Journal: J Neurol Date: 2011-03-23 Impact factor: 4.849

5. Locomotion speed determines gait variability in cerebellar ataxia and vestibular failure.

Authors: Roman Schniepp; Maximilian Wuehr; Maximilian Neuhaeusser; Maria Kamenova; Konstantin Dimitriadis; Thomas Klopstock; M Strupp; Thomas Brandt; Klaus Jahn
Journal: Mov Disord Date: 2011-10-13 Impact factor: 10.338

6. Specific influences of cerebellar dysfunctions on gait.

Authors: Winfried Ilg; Heidrun Golla; Peter Thier; Martin A Giese
Journal: Brain Date: 2007-02-07 Impact factor: 13.501

7. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine.

Authors: M Strupp; R Kalla; M Dichgans; T Freilinger; S Glasauer; T Brandt
Journal: Neurology Date: 2004-05-11 Impact factor: 9.910

8. Intensive coordinative training improves motor performance in degenerative cerebellar disease.

Authors: W Ilg; M Synofzik; D Brötz; S Burkard; M A Giese; L Schöls
Journal: Neurology Date: 2009-10-28 Impact factor: 9.910

9. 4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus.

Authors: Roger Kalla; Stefan Glasauer; Ulrich Büttner; Thomas Brandt; Michael Strupp
Journal: Brain Date: 2007-07-29 Impact factor: 13.501

10. Gait variability: methods, modeling and meaning.

Authors: Jeffrey M Hausdorff
Journal: J Neuroeng Rehabil Date: 2005-07-20 Impact factor: 4.262

10 in total

23 in total

4-aminopyridine and cerebellar gait: a retrospective case series.

1. Long-term effects of coordinative training in degenerative cerebellar disease.

2. The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.

3. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.

4. 4-Aminopyridine improves gait variability in cerebellar ataxia due to CACNA 1A mutation.

5. Locomotion speed determines gait variability in cerebellar ataxia and vestibular failure.

6. Specific influences of cerebellar dysfunctions on gait.

7. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine.

8. Intensive coordinative training improves motor performance in degenerative cerebellar disease.

9. 4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus.

10. Gait variability: methods, modeling and meaning.

1. Experience in a short-term trial with 4-aminopyridine in cerebellar ataxia.

Review 2. The treatment and natural course of peripheral and central vertigo.

3. 4-aminopyridine improves freezing of gait in Parkinson's disease.

4. Transition from downbeat to upbeat nystagmus caused by 4-aminopyridine.

Review 5. Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus.

Review 6. The physiological basis of therapies for cerebellar ataxias.

7. The interrelationship between disease severity, dynamic stability, and falls in cerebellar ataxia.

8. [Vertigo and dizziness: the neurologist's perspective].

Review 9. [Peripheral, central and functional vertigo syndromes].

10. Increased gait variability is associated with the history of falls in patients with cerebellar ataxia.